Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 11, Issue 8, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-10
DOI
10.1038/s41408-021-00534-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy
- (2021) Rémy Duléry et al. AMERICAN JOURNAL OF HEMATOLOGY
- Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
- (2021) Yair Herishanu et al. BLOOD
- Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose
- (2021) Evangelos Terpos et al. BLOOD
- Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
- (2021) Leticia Monin et al. LANCET ONCOLOGY
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
- (2021) Joseph E. Ebinger et al. NATURE MEDICINE
- Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival
- (2021) Stefania Dispinseri et al. Nature Communications
- Author Correction: Delayed production of neutralizing antibodies correlates with fatal COVID-19
- (2021) Carolina Lucas et al. NATURE MEDICINE
- CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
- (2021) Erin M. Bange et al. NATURE MEDICINE
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
- (2020) Alba Grifoni et al. CELL
- Convalescent plasma therapy for B-cell depleted patients with protracted COVID-19 disease
- (2020) Thomas Hueso et al. BLOOD
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
- (2020) Abi Vijenthira et al. BLOOD
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation
- (2016) Justyna Ogonek et al. Frontiers in Immunology
- The Xs and Y of immune responses to viral vaccines
- (2010) Sabra L Klein et al. LANCET INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search